newsfilter
← Latest News
Business Wire·

OS Therapies Provides Corporate Update

Strong cash position relative to monthly burn and cash needs into mid-2026 Significant regulatory milestones upcoming in OST-HER2 osteosarcoma program Pending acquisition paves the way for commercialization and